相似文献
1
Targeting inflammation to reduce cardiovascular disease risk.
Br J Pharmacol. 2017 Nov;174(22):3895-3897. doi: 10.1111/bph.14039.
2
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?
Br J Pharmacol. 2017 Nov;174(22):3898-3913. doi: 10.1111/bph.13818. Epub 2017 Jun 10.
3
WNT signalling: mechanisms and therapeutic opportunities.
Br J Pharmacol. 2017 Dec;174(24):4543-4546. doi: 10.1111/bph.14065.
4
Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.
Br J Pharmacol. 2017 Nov;174(22):3986-4006. doi: 10.1111/bph.13743. Epub 2017 Mar 23.
5
Molecular pharmacology of G protein-coupled receptors.
Br J Pharmacol. 2016 Oct;173(20):2931-3. doi: 10.1111/bph.13610.
6
Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.
Br J Pharmacol. 2017 Nov;174(22):3973-3985. doi: 10.1111/bph.13805. Epub 2017 May 5.
7
Unravelling the adiponectin paradox: novel roles of adiponectin in the regulation of cardiovascular disease.
Br J Pharmacol. 2017 Nov;174(22):4007-4020. doi: 10.1111/bph.13619. Epub 2016 Oct 19.
8
Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system.
Br J Pharmacol. 2017 Nov;174(22):4021-4031. doi: 10.1111/bph.13815. Epub 2017 May 16.
9
Anti-atherosclerotic effect of the angiotensin 1-7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis.
Br J Pharmacol. 2017 Nov;174(22):4055-4069. doi: 10.1111/bph.13685. Epub 2017 Feb 1.
10
Emerging areas of opioid pharmacology.
Br J Pharmacol. 2018 Jul;175(14):2715-2716. doi: 10.1111/bph.14343.
引用本文的文献
1
Association between serum 25-hydroxyvitamin d and myeloperoxidase: A cross-sectional study of a general population in China.
Front Nutr. 2022 Aug 2;9:948691. doi: 10.3389/fnut.2022.948691. eCollection 2022.
2
The HS-Donor Erucin Exhibits Protective Effects against Vascular Inflammation in Human Endothelial and Smooth Muscle Cells.
Antioxidants (Basel). 2021 Jun 15;10(6):961. doi: 10.3390/antiox10060961.
3
Obstructive Sleep Apnea as a Cardiovascular Risk Factor-Beyond CPAP.
Can J Cardiol. 2021 May;37(5):756-765. doi: 10.1016/j.cjca.2021.01.027. Epub 2021 Feb 19.
4
Mitochondrial Contact Sites in Inflammation-Induced Cardiovascular Disease.
Front Cell Dev Biol. 2020 Jul 30;8:692. doi: 10.3389/fcell.2020.00692. eCollection 2020.
5
Interleukin 10, lipid profile, vitamin D, selenium, metabolic syndrome, and serum antioxidant capacity in elderly people with and without cardiovascular disease: Amirkola health and ageing project cohort-based study.
ARYA Atheroscler. 2019 Sep;15(5):233-240. doi: 10.22122/arya.v15i5.1623.
6
Anti-inflammatory and Regulatory Effects of Huanglian Jiedu Decoction on Lipid Homeostasis and the TLR4/MyD88 Signaling Pathway in LPS-Induced Zebrafish.
Front Physiol. 2019 Sep 26;10:1241. doi: 10.3389/fphys.2019.01241. eCollection 2019.
本文引用的文献
1
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease.
N Engl J Med. 2017 Sep 21;377(12):1119-1131. doi: 10.1056/NEJMoa1707914. Epub 2017 Aug 27.
2
Inhibition of microsomal PGE synthase-1 reduces human vascular tone by increasing PGI : a safer alternative to COX-2 inhibition.
Br J Pharmacol. 2017 Nov;174(22):4087-4098. doi: 10.1111/bph.13939. Epub 2017 Aug 11.
3
Cytotoxic lymphocytes and atherosclerosis: significance, mechanisms and therapeutic challenges.
Br J Pharmacol. 2017 Nov;174(22):3956-3972. doi: 10.1111/bph.13845. Epub 2017 Jun 13.
4
Targeting inflammation to reduce cardiovascular disease risk: a realistic clinical prospect?
Br J Pharmacol. 2017 Nov;174(22):3898-3913. doi: 10.1111/bph.13818. Epub 2017 Jun 10.
5
Nitric oxide and hydrogen sulfide: the gasotransmitter paradigm of the vascular system.
Br J Pharmacol. 2017 Nov;174(22):4021-4031. doi: 10.1111/bph.13815. Epub 2017 May 16.
6
Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis.
Br J Pharmacol. 2017 Nov;174(22):3940-3955. doi: 10.1111/bph.13802. Epub 2017 May 4.
7
Vascular inflammation and low-density lipoproteins: is cholesterol the link? A lesson from the clinical trials.
Br J Pharmacol. 2017 Nov;174(22):3973-3985. doi: 10.1111/bph.13805. Epub 2017 May 5.
8
Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.
Br J Pharmacol. 2017 Nov;174(22):3986-4006. doi: 10.1111/bph.13743. Epub 2017 Mar 23.
9
Aspirin-triggered lipoxin A4 inhibits atherosclerosis progression in apolipoprotein E mice.
Br J Pharmacol. 2017 Nov;174(22):4043-4054. doi: 10.1111/bph.13707. Epub 2017 Feb 14.
10
Readapting the adaptive immune response - therapeutic strategies for atherosclerosis.
Br J Pharmacol. 2017 Nov;174(22):3926-3939. doi: 10.1111/bph.13700. Epub 2017 Feb 1.
Zotero 插件